RENOVORX, INC. (RNXT) Free cash flow
- Free cash flow · 12 months (USD): Value $-11.94M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -604.10%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-11.94M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-11.87M − $71.00K ≈ $-11.94M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -604.10% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-11.94M ÷ $1.98M × 100 ≈ -604.10% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-11.87M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.97× | Operating cash flow / net income. Period ending 2026-06-30. $-11.87M ÷ $-12.29M ≈ 0.97× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -11.87M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 71.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -11.94M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 1.98M USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -12.29M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-11.94M | (m) | $-11.87M | $71.00K | (m) | $1.98M | (m) | $-12.29M | (m) | (m) | -604.10% | 0.97× |
| 2026-03-31 | $-11.30M | (m) | $-11.30M | $0.00 | (m) | $1.49M | (m) | $-12.27M | (m) | (m) | -758.97% | 0.92× |
| 2025-12-31 | $-10.97M | (m) | $-10.97M | $2.00K | (m) | $1.12M | (m) | $-11.17M | (m) | (m) | -977.29% | 0.98× |
| 2025-09-30 | (m) | (m) | $-10.38M | (m) | (m) | (m) | (m) | $-11.11M | (m) | (m) | (m) | 0.93× |
| 2025-06-30 | (m) | (m) | $-10.31M | (m) | (m) | (m) | (m) | $-10.66M | (m) | (m) | (m) | 0.97× |
| 2025-03-31 | (m) | (m) | $-10.30M | (m) | (m) | (m) | (m) | $-10.16M | (m) | (m) | (m) | 1.01× |
| 2024-12-31 | $-9.14M | (m) | $-9.13M | $12.00K | (m) | $43.00K | (m) | $-8.81M | (m) | (m) | -21248.84% | 1.04× |
| 2024-09-30 | (m) | (m) | $-8.75M | (m) | (m) | (m) | (m) | $-9.16M | (m) | (m) | (m) | 0.95× |
| 2024-06-30 | (m) | (m) | $-9.28M | (m) | (m) | (m) | (m) | $-8.11M | (m) | (m) | (m) | 1.14× |
| 2024-03-31 | (m) | (m) | $-9.76M | (m) | (m) | (m) | (m) | $-8.05M | (m) | (m) | (m) | 1.21× |
| 2023-12-31 | (m) | (m) | $-10.26M | (m) | (m) | (m) | (m) | $-10.23M | (m) | (m) | (m) | 1.00× |
| 2023-09-30 | (m) | (m) | $-9.89M | (m) | (m) | (m) | (m) | $-9.16M | (m) | (m) | (m) | 1.08× |
| 2023-06-30 | (m) | (m) | $-9.83M | (m) | (m) | (m) | (m) | $-9.88M | (m) | (m) | (m) | 1.00× |
| 2023-03-31 | (m) | (m) | $-9.42M | (m) | (m) | (m) | (m) | $-10.14M | (m) | (m) | (m) | 0.93× |
| 2022-12-31 | (m) | (m) | $-8.81M | (m) | (m) | (m) | (m) | $-9.89M | (m) | (m) | (m) | 0.89× |
| 2022-09-30 | (m) | (m) | $-9.69M | (m) | (m) | (m) | (m) | $-10.09M | (m) | (m) | (m) | 0.96× |
| 2022-06-30 | (m) | (m) | $-8.13M | (m) | (m) | (m) | (m) | $-9.46M | (m) | (m) | (m) | 0.86× |
| 2022-03-31 | (m) | (m) | $-7.02M | (m) | (m) | (m) | (m) | $-8.18M | (m) | (m) | (m) | 0.86× |
| 2021-12-31 | (m) | (m) | $-5.92M | (m) | (m) | (m) | (m) | $-6.32M | (m) | (m) | (m) | 0.94× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-3.90M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $-3.53M | (m) | (m) | (m) | (m) | $-3.80M | (m) | (m) | (m) | 0.93× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |